APA (7th ed.) Citation

J, C., AV, E., S, C., BJ, L., JE, K., ACA, T., . . . ES, K. (2025). Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. Journal of medicinal chemistry, 68(6), 6064. https://doi.org/10.1021/acs.jmedchem.4c02314

Chicago Style (17th ed.) Citation

J, Cregg, et al. "Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers." Journal of Medicinal Chemistry 68, no. 6 (2025): 6064. https://doi.org/10.1021/acs.jmedchem.4c02314.

MLA (9th ed.) Citation

J, Cregg, et al. "Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers." Journal of Medicinal Chemistry, vol. 68, no. 6, 2025, p. 6064, https://doi.org/10.1021/acs.jmedchem.4c02314.